Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.80 |
| ▸ | EYA3 | Q99504 | 7/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.60 |
| ▸ | TTR | P02766 | 4/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.50 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287450 | 0.89 | SLC22A12 (1.00) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| SCHEMBL1287903 | 0.86 | SLC22A12 (0.72) | SLC22A12EYA3CYP2C9CYP2C19LMNA | |
| SCHEMBL6336521 | 0.84 | SLC22A12 (0.80) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| SCHEMBL1287381 | 0.84 | SLC22A12 (0.78) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| SCHEMBL1287502 | 0.82 | SLC22A12 (1.00) | SLC22A12EYA3CYP2C9CYP2C19LMNA | |
| Cyanide SCHEMBL28104495 | 0.81 | SLC22A12 (0.54) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| SCHEMBL28104784 | 0.81 | SLC22A12 (0.54) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| SCHEMBL1287413 | 0.81 | SLC22A12 (1.00) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| Benzarone SCHEMBL555497 | 0.81 | EYA3 (1.00) | SLC22A12EYA3CYP2C9TTRPTPN1 | |
| Benzarone SCHEMBL29576057 | 0.81 | EYA3 (1.00) | SLC22A12EYA3CYP2C9TTRPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | J-PHARMA CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012048058-A2 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | SLCO2B1, SLCO2A1, SLC10A6 | SLC22A12 19/4885EYA3 4828/4885CYP2C9 203/4885 |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | SLCO2B1, SLCO2A1, SLC10A6 | SLC22A12 19/4885EYA3 4828/4885CYP2C9 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.